Press Releases
The American Association for Cancer Research (AACR) is now accepting submissions of ideas for the Stand Up To Cancer (SU2C)-American Cancer Society Lung Cancer Translational Research Dream Team Grant that will offer up to $20 million in research funding, with the Society and SU2C each providing half the funds over a three-year period. Bristol-Myers Squibb will provide funding in the amount of $5 million to SU2C that will support this Dream Team.
The grant provides funding for research projects that must include therapeutic interventions for lung cancer and deliver near-term patient benefit through investigation by a multidisciplinary, multi-institutional Dream Team of experts. The research will be expected to involve new immunological approaches. Proposals for the grant must describe plans indicating how the group will use a transformative and synergistic approach, and how the work will be translated into the clinic. To maximize creativity, innovation, and collaboration, the projects should span multiple disciplines and use modern scientific tools to attack research questions in a coordinated effort.
A SU2C-American Cancer Society Joint Scientific Advisory Committee (JSAC) will conduct a unique, interactive, rapid, and rigorous evaluation of the applications via a multistep scientific review process. The JSAC is comprised of highly accomplished senior laboratory researchers and physician-scientists, as well as advocates.
The committee is chaired by Nobel Laureate Phillip A. Sharp, PhD, institute professor at the David H. Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology in Cambridge. Arnold J. Levine, PhD, professor at the Institute for Advanced Study in Princeton, New Jersey, and at the Cancer Institute of New Jersey in New Brunswick, and William H. Chambers, PhD, national vice president, extramural research, at the American Cancer Society will serve as vice-chairs.
Letters of Intent for the SU2C-American Cancer Society Lung Cancer Translational Research Dream Team Grant are due by noon ET, Nov. 5, 2014, via proposalCENTRAL at https://proposalcentral.altum.com.
Learn more about general information on eligibility criteria, the application process, and other details about Dream Team grants by visiting: http://www.aacr.org/FUNDING/PAGES/SUTC-LISTING.ASPX.
Inquiries may be directed to the AACR Scientific Review and Grants Administration Department at 267-765-1049 or su2c@aacr.org.
The SU2C-American Cancer Society Lung Cancer Translational Research Dream Team Grant recipients are scheduled to be announced in spring 2015.